diabetes mellitus type 2
Item
type 2 diabetes mellitus
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
diet therapy; sulphonylurea or repaglinide
Item
diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
boolean
C0012159 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
C0246689 (UMLS CUI [3])
hba1c
Item
hba1c for diet treated subjects 6.5-12%, both inclusive
boolean
C0019018 (UMLS CUI [1])
hba1c for sulphonylurea or repaglinide treated subjects
Item
hba1c for sulphonylurea or repaglinide treated subjects maximum 10%
boolean
C0038766 (UMLS CUI [1,1])
C0019018 (UMLS CUI [1,2])
C0246689 (UMLS CUI [2,1])
C0019018 (UMLS CUI [2,2])
bmi
Item
body mass index (bmi) at least 27 kg/m^2
boolean
C1305855 (UMLS CUI [1])
euthyroid
Item
euthyroid subjects
boolean
C0117002 (UMLS CUI [1])
fasting blood glucose
Item
fasting blood glucose 7-14 mmol/l
boolean
C0428568 (UMLS CUI [1])
impaired liver function
Item
impaired liver function
boolean
C0086565 (UMLS CUI [1])
impaired renal function
Item
impaired renal function
boolean
C0151746 (UMLS CUI [1])
cardiac problems
Item
cardiac problems
boolean
C0262402 (UMLS CUI [1])
hypertension
Item
uncontrolled treated/untreated hypertension
boolean
C0020538 (UMLS CUI [1])
hypoglycaemia
Item
recurrent severe hypoglycaemia as judged by the investigator
boolean
C0020615 (UMLS CUI [1])
allergy to trial product
Item
known or suspected allergy to trial product or related products
boolean
C0020517 (UMLS CUI [1])
medication
Item
use of any drug (except for ohas (oral hypoglycaemic agents), which in the investigator's opinion could interfere with the glucose level or body weight. stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
boolean
C0013227 (UMLS CUI [1,1])
C0202042 (UMLS CUI [1,2])
C0005910 (UMLS CUI [1,3])